A. A. Puchkov
A. A. Puchkov has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- A. M. Mitrofanova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
1 shared publication - A. Yu. Sushchenko
Stavropol Regional Children’s Clinical Hospital
1 shared publication - Alexander N. Obedin
Stavropol State Medical University
1 shared publication - Artem Evgenevich Mishvelov
Stavropol State Medical University
1 shared publication - Galina A. Bykova
Ural State Medical University; Sverdlovsk Clinical Regional Hospital No. 2
1 shared publication - Garik B. Sagoyan
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 146-152
Intelligent decision support systems for physicians in renal tumors
Introduction . Malignant neoplasms of the kidney remain one of the most significant problems in modern oncourology and pediatric oncology. According to the World Health Organization (2024), more than 430,000 new cases of malignant renal neoplasms are registered worldwide annually, of which approximately 5–7% occur in patients under 18 years of age. The purpose of the study – to demonstrate how intelligent software solutions improve diagnosis and treatment planning in children and adolescents with renal neoplasms, based on clinical cases from real-world practice. Materials and methods . A series of three cases examined and treated at the Stavropol Regional Children’s Clinical Hospital and the N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia is presented. Medvision AI (automated segmentation and 3D modeling), standard computer/magnetic resonance imaging protocols, and histological verification were used. Results . Intelligent tools provided more accurate delineation of tumor contours compared with analogs (Viewer “Kometa 3Di PACS”, Radiant), clarified relationships with vascular structures, and enabled quantitative assessment of lesion volume. Preoperative diagnosis fully matched morphological findings in 3 out of 3 cases, without specification of the histological tumor subtype. In one case, 3D planning changed the surgical strategy in favor of organ-sparing resection. No intraoperative complications were observed; visualization reduced the number of intraoperative errors and increased concordance between the surgical plan and the surgeon’s actual actions. Conclusions . Integration of Medvision AI into routine practice is feasible, safe, and clinically beneficial: it assists in determining the extent of surgical intervention and supports personalized decision-making. Prospective multicenter studies are required to quantitatively assess its impact on outcomes and resource efficiency.
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 146-152
Open AccessIntelligent decision support systems for physicians in renal tumors
Introduction . Malignant neoplasms of the kidney remain one of the most significant problems in modern oncourology and pediatric oncology. According to the World Health Organization (2024), more than 430,000 new cases of malignant renal neoplasms are registered worldwide annually, of which approximately 5–7% occur in patients under 18 years of age. The purpose of the study – to demonstrate how intelligent software solutions improve diagnosis and treatment planning in children and adolescents with renal neoplasms, based on clinical cases from real-world practice. Materials and methods . A series of three cases examined and treated at the Stavropol Regional Children’s Clinical Hospital and the N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia is presented. Medvision AI (automated segmentation and 3D modeling), standard computer/magnetic resonance imaging protocols, and histological verification were used. Results . Intelligent tools provided more accurate delineation of tumor contours compared with analogs (Viewer “Kometa 3Di PACS”, Radiant), clarified relationships with vascular structures, and enabled quantitative assessment of lesion volume. Preoperative diagnosis fully matched morphological findings in 3 out of 3 cases, without specification of the histological tumor subtype. In one case, 3D planning changed the surgical strategy in favor of organ-sparing resection. No intraoperative complications were observed; visualization reduced the number of intraoperative errors and increased concordance between the surgical plan and the surgeon’s actual actions. Conclusions . Integration of Medvision AI into routine practice is feasible, safe, and clinically beneficial: it assists in determining the extent of surgical intervention and supports personalized decision-making. Prospective multicenter studies are required to quantitatively assess its impact on outcomes and resource efficiency.
- 19 February 2026
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 4,p. 147-156
COCKAYNE SYNDROME TYPE II
Cockayne syndrome (CS) is a rare autosomal recessive neurodegenerative disorder associated with impaired DNA repair, developmental delay, and multisystem involvement. This article presents a rare clinical case of type II CS in a child with a confirmed ERCC6 gene mutation and a severe disease course. Symptoms manifested in the neonatal period and progressed with profound neurological deficits, sensorineural hearing loss, ophthalmologic disorders, epileptic syndrome, and persistent malnutrition. A distinctive feature of this case is the unusually long survival (up to 17 years), which is exceptional for CS type II, typically associated with a poor prognosis. The diagnosis was confirmed by molecular genetic testing, and neuroimaging revealed characteristic brain abnormalities. The patient received supportive care based on a multidisciplinary approach, including nutritional, symptomatic, antiepileptic, and palliative treatment. The condition remained stably severe and required continuous medical supervision. This case emphasizes the importance of early diagnosis, ongoing multidisciplinary management, and clinical vigilance in children with rare neurodegenerative disorders.
- 19 February 2026
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 4,p. 147-156
COCKAYNE SYNDROME TYPE II
Cockayne syndrome (CS) is a rare autosomal recessive neurodegenerative disorder associated with impaired DNA repair, developmental delay, and multisystem involvement. This article presents a rare clinical case of type II CS in a child with a confirmed ERCC6 gene mutation and a severe disease course. Symptoms manifested in the neonatal period and progressed with profound neurological deficits, sensorineural hearing loss, ophthalmologic disorders, epileptic syndrome, and persistent malnutrition. A distinctive feature of this case is the unusually long survival (up to 17 years), which is exceptional for CS type II, typically associated with a poor prognosis. The diagnosis was confirmed by molecular genetic testing, and neuroimaging revealed characteristic brain abnormalities. The patient received supportive care based on a multidisciplinary approach, including nutritional, symptomatic, antiepileptic, and palliative treatment. The condition remained stably severe and required continuous medical supervision. This case emphasizes the importance of early diagnosis, ongoing multidisciplinary management, and clinical vigilance in children with rare neurodegenerative disorders.